Intellia Therapeutics

Intellia Therapeutics is a publicly traded biotechnology company, so investment decisions are made by its board of directors and executive team, led by CEO John Leonard, M.D. (appointed January 2018). Key executives include CFO Edward Dulac and Chief Medical Officer David Lebwohl, M.D. The board is chaired by Frank Verwiel, M.D., and includes experienced pharma and biotech investors.

Intellia develops its CRISPR-based therapies in-house, leveraging its core gene-editing platform and partnerships. The company collaborates with Regeneron on liver-directed programs, co-founded AvenCell for allogeneic CAR-T therapies with Blackstone Life Sciences, and has a licensing agreement with Kyverna Therapeutics for autoimmune cell therapies. It also scouts cutting-edge technologies to advance its platform.

Intellia Therapeutics is a clinical-stage biotechnology company, not a family office. It is publicly traded on Nasdaq under the ticker NTLA. The firm focuses on developing CRISPR-based therapeutics and does not manage external capital or operate as an investment vehicle. Its structure is that of a drug development company with a board of directors and executive management.

Intellia's most advanced programs target hereditary angioedema (HAE) and ATTR amyloidosis, both in late-stage clinical development. The company uses in vivo CRISPR editing to treat these genetic diseases. Additional pipeline candidates include ex vivo engineered cell therapies for cancer and autoimmune indications, with partnerships for allogeneic CAR-T programs via AvenCell and Kyverna.

Jennifer Doudna, who shared the 2020 Nobel Prize in Chemistry for co-developing CRISPR-Cas9 gene editing, is a co-founder of Intellia Therapeutics. The company was built to translate that foundational science into human therapeutics. Doudna does not serve in a management role at Intellia, but the firm's platform directly descends from the CRISPR technology she pioneered.

Yes. Intellia has a major collaboration with Regeneron to research, develop, and commercialize CRISPR-based therapies for liver diseases, including its lead ATTR amyloidosis program. Additionally, it co-founded AvenCell with Blackstone Life Sciences for allogeneic CAR-T cell therapy. The firm also partners with Kyverna Therapeutics on autoimmune disease cell therapies.

Intellia is building a fully integrated commercial infrastructure under the leadership of Chief Technical Officer Eliana Clark, who oversees manufacturing, supply chain, process development, and quality. The firm intends to become a self-sustaining biopharmaceutical company with capabilities from drug discovery through commercialization, rather than licensing out its products.